Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#191 / 200 Total
TBBB - BBB Foods Inc - Stock Price Chart
TickerTBBB [NYSE]
CompanyBBB Foods Inc
CountryMexico
IndustryDiscount Stores
Market Cap2.63BEPS (ttm)-
P/E-EPS this Y102.02%
Forward P/E63.43EPS next Y332.28%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B14.20EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own66.21%Inst Own29.86%
Insider Trans0.00%Inst Trans-
Short Float5.01%EarningsMay 22/a
Analyst Recom2.14Target Price28.97
Avg Volume1.05M52W Range18.71 - 28.84
BBB Foods, Inc. engages in the provision of a limited assortment of products that cover the daily grocery needs. It offers the grocery hard discount model where products offered are generally value for money. The company was founded by K. Anthony Hatoum on July 9, 2004 and is headquartered in Mexico City.
LXRX - Lexicon Pharmaceuticals Inc - Stock Price Chart
TickerLXRX [NASD, RUT]
CompanyLexicon Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap668.76MEPS (ttm)-0.82
P/E-EPS this Y11.96%
Forward P/E-EPS next Y18.80%
PEG-EPS past 5Y6.80%
P/S289.50EPS next 5Y-
P/B1.58EPS Q/Q-16.69%
Dividend-Sales Q/Q4608.33%
Insider Own2.81%Inst Own62.52%
Insider Trans0.00%Inst Trans11.63%
Short Float7.16%EarningsMay 02/a
Analyst Recom1.67Target Price6.20
Avg Volume2.86M52W Range0.92 - 3.73
Jun-21-24 08:00AM Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes (GlobeNewswire) +5.71%
Jun-19-24 08:00AM Data From Lexicon's RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association (GlobeNewswire)
Jun-18-24 08:00AM Analysis of INPEFA (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology (GlobeNewswire)
Jun-14-24 08:00AM Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association (GlobeNewswire)
May-30-24 04:45AM Lexicon selects Medidata to advance Phase IIb non-opioid pain drug trial (Clinical Trials Arena)
May-29-24 07:30AM Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024 (GlobeNewswire)
May-14-24 08:03AM Lexicon Pharmaceuticals Says Post Hoc Analysis of Infepa Trial Showed Decreased Heart Failure Risk; Shares Gain Pre-Bell (MT Newswires)
07:00AM New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction (GlobeNewswire)
May-09-24 07:30AM Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024 (GlobeNewswire) +6.78%
May-06-24 10:05AM Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2024 Earnings Call Transcript (Insider Monkey) +5.17%
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Amouyal PhilippeDirectorApr 28 '24Option Exercise0.008,0320248,364Apr 29 04:16 PM
BARKER SAM LDirectorApr 28 '24Option Exercise0.008,032087,649Apr 29 04:17 PM
LEFKOWITZ ROBERT J MDDirectorApr 28 '24Option Exercise0.008,032048,364Apr 29 04:18 PM
DEBBANE RAYMONDDirectorApr 28 '24Option Exercise0.008,03201,348,879Apr 29 04:17 PM
Swain Judith LDirectorApr 28 '24Option Exercise0.008,032048,364Apr 29 04:21 PM
LGCL - Lucas GC Ltd - Stock Price Chart
TickerLGCL [NASD]
CompanyLucas GC Ltd
CountryChina
IndustrySoftware - Application
Market Cap176.07MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own88.43%Inst Own0.29%
Insider Trans0.00%Inst Trans-
Short Float1.22%Earnings-
Analyst Recom-Target Price-
Avg Volume301.39K52W Range1.88 - 5.00
Lucas GC Ltd. engages in providing recruitment and outsourcing services through its subsidiaries The company was founded by Howard Lee on August 15, 2022 and is headquartered in Beijing, China.
AMCX - AMC Networks Inc - Stock Price Chart
TickerAMCX [NASD, RUT]
CompanyAMC Networks Inc
CountryUSA
IndustryEntertainment
Market Cap481.80MEPS (ttm)3.57
P/E3.06EPS this Y-31.19%
Forward P/E2.38EPS next Y-7.11%
PEG-EPS past 5Y-8.34%
P/S0.19EPS next 5Y-12.20%
P/B0.45EPS Q/Q-56.55%
Dividend-Sales Q/Q-16.86%
Insider Own29.07%Inst Own65.59%
Insider Trans-0.43%Inst Trans-1.67%
Short Float13.41%EarningsMay 10/b
Analyst Recom3.89Target Price12.50
Avg Volume1.27M52W Range9.46 - 20.97
AMC Networks, Inc. is a holding company, which engages in the owning and management of cable television networks through its subsidiaries. It operates through the Domestic Operations, and International and Other segments. The Domestic Operations segment includes programming services, and AMC broadcasting and technology. The International and Other segment focuses on its international programming businesses. The company was founded by Charles Francis Dolan on March 9, 2011 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kelleher KimberlyChief Commercial OfficerMay 23 '24Sale17.2210,941188,4040May 28 05:42 PM
O'Connell PatrickEVP & Chief Financial OfficerMay 21 '24Sale16.326,459105,3870May 22 08:44 AM
Sherin Michael J. IIIEVP & Chief Accounting OfficerMay 21 '24Sale16.114,94879,6920May 22 08:28 AM
O'Connell PatrickEVP & Chief Financial OfficerMay 16 '24Sale16.025,00080,1006,459May 17 05:19 PM
Gallagher JamesEVP and General CounselMay 14 '24Sale15.5425,000388,5001,659May 15 04:24 PM
SPRY - ARS Pharmaceuticals Inc - Stock Price Chart
TickerSPRY [NASD, RUT]
CompanyARS Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap791.67MEPS (ttm)-0.52
P/E-EPS this Y-7.02%
Forward P/E-EPS next Y4.10%
PEG-EPS past 5Y-1.44%
P/S79167.30EPS next 5Y-
P/B3.52EPS Q/Q32.81%
Dividend-Sales Q/Q-100.00%
Insider Own51.11%Inst Own34.87%
Insider Trans-0.41%Inst Trans15.32%
Short Float14.40%EarningsMay 09/a
Analyst Recom1.00Target Price19.00
Avg Volume541.37K52W Range2.55 - 11.27
ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lowenthal Richard EPRESIDENT AND CEOJun 12 '24Sale9.1595,862876,6631,546,494Jun 13 04:30 PM
Tanimoto SarinaCHIEF MEDICAL OFFICERJun 12 '24Sale9.1595,862876,6631,546,494Jun 13 04:30 PM
Lowenthal Richard EPRESIDENT AND CEOJun 11 '24Sale9.004,13837,2541,594,328Jun 13 04:30 PM
Tanimoto SarinaCHIEF MEDICAL OFFICERJun 11 '24Sale9.004,13837,2541,594,328Jun 13 04:30 PM
Lowenthal Richard EPRESIDENT AND CEOMay 16 '24Sale9.0689,096807,0231,597,447May 16 07:51 PM
IMNN - Imunon Inc - Stock Price Chart
TickerIMNN [NASD]
CompanyImunon Inc
CountryUSA
IndustryBiotechnology
Market Cap10.53MEPS (ttm)-2.02
P/E-EPS this Y3.09%
Forward P/E-EPS next Y21.66%
PEG-EPS past 5Y26.62%
P/S-EPS next 5Y-
P/B1.24EPS Q/Q22.33%
Dividend-Sales Q/Q-
Insider Own1.15%Inst Own3.57%
Insider Trans0.00%Inst Trans-33.45%
Short Float3.48%EarningsMay 13/b
Analyst Recom1.00Target Price10.00
Avg Volume120.61K52W Range0.48 - 2.00
Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.
BRNS - Barinthus Biotherapeutics Plc. ADR - Stock Price Chart
TickerBRNS [NASD]
CompanyBarinthus Biotherapeutics Plc. ADR
CountryUnited Kingdom
IndustryBiotechnology
Market Cap51.41MEPS (ttm)-1.84
P/E-EPS this Y-4.19%
Forward P/E-EPS next Y-8.38%
PEG-EPS past 5Y-
P/S151.22EPS next 5Y-
P/B0.30EPS Q/Q17.28%
Dividend-Sales Q/Q-100.00%
Insider Own7.52%Inst Own17.36%
Insider Trans0.00%Inst Trans55.36%
Short Float0.02%EarningsMay 13/b
Analyst Recom1.50Target Price5.80
Avg Volume25.32K52W Range1.21 - 5.10
Barinthus Biotherapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. It also focuses on the pipeline of both clinical and preclinical stage therapeutic, and prophylactic programs. The company was founded by Adrian Hill and Dame Sarah Gilbert in March 2021 and is headquartered in Didcot, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Scheeren JosephDirectorJun 26 '23Buy2.4410,00024,40023,000Jun 28 07:52 AM
PHVS - Pharvaris NV - Stock Price Chart
TickerPHVS [NASD]
CompanyPharvaris NV
CountryNetherlands
IndustryBiotechnology
Market Cap1.03BEPS (ttm)-2.56
P/E-EPS this Y12.57%
Forward P/E-EPS next Y-9.33%
PEG-EPS past 5Y-28.27%
P/S-EPS next 5Y20.59%
P/B2.64EPS Q/Q21.19%
Dividend-Sales Q/Q-
Insider Own64.76%Inst Own30.94%
Insider Trans0.00%Inst Trans-0.09%
Short Float0.61%EarningsMay 08/a
Analyst Recom1.50Target Price32.27
Avg Volume71.82K52W Range10.50 - 33.00
Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Johannes Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.
DBX - Dropbox Inc - Stock Price Chart
TickerDBX [NASD]
CompanyDropbox Inc
CountryUSA
IndustrySoftware - Infrastructure
Market Cap7.31BEPS (ttm)1.50
P/E14.71EPS this Y8.11%
Forward P/E9.62EPS next Y7.44%
PEG1.89EPS past 5Y-
P/S2.90EPS next 5Y7.80%
P/B-EPS Q/Q96.31%
Dividend-Sales Q/Q3.31%
Insider Own27.66%Inst Own74.12%
Insider Trans-0.59%Inst Trans-1.82%
Short Float7.81%EarningsMay 09/a
Analyst Recom2.79Target Price27.86
Avg Volume4.30M52W Range20.68 - 33.43
Dropbox, Inc. engages in providing file backup, sync, and sharing solutions. Its products include Dropbox, Dropbox Dash beta, Dropbox Backup, Dropbox Replay, Dropbox Sign, Dropbox Capture, DocSend, and Dropbox Early Access. The company was founded by Andrew W. Houston and Arash Ferdowsi in May 2007 and is headquartered in San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Volkmer BartChief Legal OfficerJun 17 '24Sale21.026,908145,174340,934Jun 20 04:13 PM
Regan TimothyChief Financial OfficerJun 17 '24Sale20.933,00062,781551,122Jun 20 04:13 PM
Cox EricChief Customer OfficerJun 10 '24Sale21.278,536181,579350,471Jun 12 04:07 PM
Houston AndrewChief Executive OfficerJun 03 '24Sale22.4082,0001,836,4060Jun 05 04:04 PM
Peacock KarenDirectorMay 29 '24Sale23.0210,000230,17823,852May 31 04:18 PM
RBKB - Rhinebeck Bancorp Inc - Stock Price Chart
TickerRBKB [NASD]
CompanyRhinebeck Bancorp Inc
CountryUSA
IndustryBanks - Regional
Market Cap88.45MEPS (ttm)0.44
P/E18.31EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y0.69%
P/S1.31EPS next 5Y-
P/B0.77EPS Q/Q42.82%
Dividend-Sales Q/Q7.51%
Insider Own60.23%Inst Own15.31%
Insider Trans0.00%Inst Trans2.34%
Short Float0.45%Earnings-
Analyst Recom-Target Price-
Avg Volume4.15K52W Range6.10 - 9.51
Rhinebeck Bancorp, Inc. operates as a bank holding company, which engages in the provision of banking services. It operates through the following segments: Commercial Real Estate, Residential Real Estate, Commercial and Industrial, and Consumer. The Commercial Estate segment is involved in construction, non-residential, and multi-family. The Residential Real Estate Segment focuses on borrower's residential real estate generally in a first lien position. The Commercial and Industrial segment includes loans made for purposes of financing the activities of commercial customers. The Consumer segment engages in indirect automobile loans, home equity loans, and other consumer loans. The company was founded in August 2018 and is headquartered in Poughkeepsie, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bloom Jamie J.Chief Operating OfficerDec 06 '23Sale6.256003,75035Dec 06 01:47 PM
Bloom Jamie J.Chief Operating OfficerDec 05 '23Sale6.372,23414,228635Dec 06 01:47 PM
Tumolo Louis Jr.DirectorDec 01 '23Buy6.302,00012,60030,128Dec 04 04:36 PM
Tumolo Louis Jr.DirectorNov 30 '23Buy6.332,00012,67028,128Dec 04 04:36 PM
110151617181920